GSE33258

Gene expression profiling in HCV associated liver disease

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

36 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Expression of human genes was compared in liver fibrosis stage F1, F2, F3, and F4 to find markers that can differentiate among each fibrosis stages and cirrhosis.

Overall design

Four- condition experiment, F1 vs. F2 vs. F3 vs. F4. Biological replicates: 3 Normal, 3 F1, 3 F2, 3 F3 and 3 F4 stage samples.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
36 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

2 linked publications 2 DOIs

Primary publication

  1. HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. Genes & diseases, 2019
  2. Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. Journal of translational medicine, 2012
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Fibrosis, liver fibrosis Disease context came from Normalization rules.
  • Likely case group Liver fibrosis 36 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Biopsy. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Fibrosis, Infectious disease or host response, Liver fibrosis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 2 publications; 2 DOIs available: PMID 22397681, PMID 32042870.
  • Publication context: Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray.. Journal of translational medicine, 2012. PMID 22397681. DOI 10.1186/1479-5876-10-41.
  • Publication context: HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers.. Genes & diseases, 2019. PMID 32042870. DOI 10.1016/j.gendis.2019.04.007.

Cautions

  • Comparison: Unclear study design. Specimen: Biopsy. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Biopsy. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

221 fields

Sample Group Preview

36 rows shown
Show Hide
Study totals: Case 36 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 36 rows shown
Group Role Accession Title Source / characteristics Reason
Liver fibrosis Case GSM822892 N1_Fibrosis stage 1_1 N1_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822893 N1_Fibrosis stage 1_2 N1_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822894 N1_Fibrosis stage 1_3 N1_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822895 N2_Fibrosis stage 1_1 N2_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822896 N2_Fibrosis stage 1_2 N2_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822897 N2_Fibrosis stage 1_3 N2_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822898 N3_Fibrosis stage 1_1 N3_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822899 N3_Fibrosis stage 1_2 N3_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822900 N3_Fibrosis stage 1_3 N3_Fibrosis stage 1 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F1 Case marker detected.
Liver fibrosis Case GSM822901 N1_Fibrosis stage 2_1 N1_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822902 N1_Fibrosis stage 2_2 N1_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822903 N1_Fibrosis stage 2_3 N1_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822904 N2_Fibrosis stage 2_1 N2_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822905 N2_Fibrosis stage 2_2 N2_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822906 N2_Fibrosis stage 2_3 N2_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822907 N3_Fibrosis stage 2_1 N3_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822908 N3_Fibrosis stage 2_2 N3_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822909 N3_Fibrosis stage 2_3 N3_Fibrosis stage 2 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F2 Case marker detected.
Liver fibrosis Case GSM822910 N1_Fibrosis stage 3_1 N1_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822911 N1_Fibrosis stage 3_2 N1_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822912 N1_Fibrosis stage 3_3 N1_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822913 N2_Fibrosis stage 3_1 N2_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822914 N2_Fibrosis stage 3_2 N2_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822915 N2_Fibrosis stage 3_3 N2_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822916 N3_Fibrosis stage 3_1 N3_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822917 N3_Fibrosis stage 3_2 N3_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822918 N3_Fibrosis stage 3_3 N3_Fibrosis stage 3 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F3 Case marker detected.
Liver fibrosis Case GSM822919 N1_Fibrosis stage 4_1 N1_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822920 N1_Fibrosis stage 4_2 N1_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822921 N1_Fibrosis stage 4_3 N1_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822922 N2_Fibrosis stage 4_1 N2_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822923 N2_Fibrosis stage 4_2 N2_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822924 N2_Fibrosis stage 4_3 N2_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822925 N3_Fibrosis stage 4_1 N3_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822926 N3_Fibrosis stage 4_2 N3_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.
Liver fibrosis Case GSM822927 N3_Fibrosis stage 4_3 N3_Fibrosis stage 4 Tissue: HCV infected human liver biopsy samples; Liver fibrosis stage: F4 Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.